Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504028 | 1.00 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1PEPDMEN1 | |
| SCHEMBL504027 | 1.00 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1PEPDMEN1 | |
| SCHEMBL11597749 | 1.00 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1PEPDMEN1 | |
| SCHEMBL9019456 | 0.95 | SLC1A2 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL19733794 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL20979921 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL19733793 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL20979912 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL20226843 | 0.93 | HSD11B1 (0.39) | SLC1A2SLC1A1GABRR1MEN1BLM | |
| SCHEMBL11695757 | 0.93 | PEPD (0.43) | GABRR1PEPDMEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | SLC1A2 4633/4885SLC1A1 4486/4885GABRR1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.